Atrial Fibrillation in Patients with Heart Failure: Current State and Future Directions

  • Tuoyo O. Mene-Afejuku
  • Persio D. López
  • Adedoyin Akinlonu
  • Carissa Dumancas
  • Ferdinand Visco
  • Savi Mushiyev
  • Gerald Pekler
Review Article
  • 68 Downloads

Abstract

Heart failure affects nearly 26 million people worldwide. Patients with heart failure are frequently affected with atrial fibrillation, and the interrelation between these pathologies is complex. Atrial fibrillation shares the same risk factors as heart failure. Moreover, it is associated with a higher-risk baseline clinical status and higher mortality rates in patients with heart failure. The mechanisms by which atrial fibrillation occurs in a failing heart are incompletely understood, but animal studies suggest they differ from those that occur in a healthy heart. Data suggest that heart failure-induced atrial fibrosis and atrial ionic remodeling are the underlying abnormalities that facilitate atrial fibrillation. Therapeutic considerations for atrial fibrillation in patients with heart failure include risk factor modification and guideline-directed medical therapy, anticoagulation, rate control, and rhythm control. As recommended for atrial fibrillation in the non-failing heart, anticoagulation in patients with heart failure should be guided by a careful estimation of the risk of embolic events versus the risk of hemorrhagic episodes. The decision whether to target a rate-control or rhythm-control strategy is an evolving aspect of management. Currently, both approaches are good medical practice, but recent data suggest that rhythm control, particularly when achieved through catheter ablation, is associated with improved outcomes. A promising field of research is the application of neurohormonal modulation to prevent the creation of the “structural substrate” for atrial fibrillation in the failing heart.

Notes

Acknowledgements

The authors wholeheartedly thank Dr. Nora Bergasa for dedicating her time to proofreading this paper and providing valuable insight.

Compliance with Ethical Standards

Conflict of interest

Drs. Tuoyo O. Mene-Afejuku, Persio D. López, Adedoyin Akinlonu, Carissa Dumancas, Ferdinand Visco, Savi Mushiyev, and Gerald Pekler have no conflicts of interest or financial ties to disclose.

Funding

No external funding was used to prepare this manuscript.

References

  1. 1.
    Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61:391–403.PubMedCrossRefGoogle Scholar
  3. 3.
    Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN, Gheorghiade M. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123–33.PubMedCrossRefGoogle Scholar
  4. 4.
    Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93:1137–46.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Dokainish H, Teo K, Zhu J, Roy A, AlHabib KF, ElSayed A, Palileo-Villaneuva L, Lopez-Jaramillo P, Karaye K, Yusoff K, Orlandini A, Sliwa K, Mondo C, Lanas F, Prabhakaran D, Badr A, Elmaghawry M, Damasceno A, Tibazarwa K, Belley-Cote E, Balasubramanian K, Yacoub MH, Huffman MD, Harkness K, Grinvalds A, McKelvie R, Yusuf S, INTER-CHF I. Heart Failure in Africa, Asia, the Middle East and South America: the INTER-CHF study. Int J Cardiol. 2016;204:133–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Verma A, Kalman JM, Callans DJ. Treatment of patients with atrial fibrillation and heart failure with reduced ejection fraction. Circulation. 2017;135:1547–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Lip GY, Heinzel FR, Gaita F, Juanatey JR, Le Heuzey JY, Potpara T, Svendsen JH, Vos MA, Anker SD, Coats AJ, Haverkamp W, Manolis AS, Chung MK, Sanders P, Pieske B, Gorenek B, Lane D, Boriani G, Linde C, Hindricks G, Tsutsui H, Homma S, Brownstein S, Nielsen JC, Lainscak M, Crespo-Leiro M, Piepoli M, Seferovic P, Savelieva I. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2016;18:12–36.PubMedCrossRefGoogle Scholar
  8. 8.
    Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–25.PubMedCrossRefGoogle Scholar
  9. 9.
    Rose-Jones LJ, Bode WD, Gehi AK. Current approaches to antiarrhythmic therapy in heart failure. Heart Fail Clin. 2014;10:635–52.PubMedCrossRefGoogle Scholar
  10. 10.
    Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120:1501–17.PubMedCrossRefGoogle Scholar
  11. 11.
    Seiler J, Stevenson WG. Atrial fibrillation in congestive heart failure. Cardiol Rev. 2010;18:38–50.PubMedCrossRefGoogle Scholar
  12. 12.
    Ozierański K, Kapłon-Cieślicka A, Peller M, Tymińska A, Balsam P, Galas M, Marchel M, Crespo-Leiro M, Maggioni AP, Drożdż J, Opolski G. Clinical characteristics and predictors of one-year outcome of heart failure patients with atrial fibrillation compared to heart failure patients in sinus rhythm. Kardiol Pol. 2016;74:251–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail. 2009;11:676–83.PubMedCrossRefGoogle Scholar
  14. 14.
    Yamauchi T, Sakata Y, Miura M, Tadaki S, Ushigome R, Sato K, Onose T, Tsuji K, Abe R, Oikawa T, Kasahara S, Nochioka K, Takahashi J, Miyata S, Shimokawa H, CHART-2 I. Prognostic impact of new-onset atrial fibrillation in patients with chronic heart failure—a report from the CHART-2 Study. Circ J. 2016;80:157–67.PubMedCrossRefGoogle Scholar
  15. 15.
    Ford I, Robertson M, Komajda M, Böhm M, Borer JS, Tavazzi L, Swedberg K, SHIFT I. Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model. Int J Cardiol. 2015;184:163–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA, CHARM I. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006;47:1997–2004.PubMedCrossRefGoogle Scholar
  17. 17.
    Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, Odim J, Laks H, Sen L. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation. 2004;109:363–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Anyukhovsky EP, Sosunov EA, Plotnikov A, Gainullin RZ, Jhang JS, Marboe CC, Rosen MR. Cellular electrophysiologic properties of old canine atria provide a substrate for arrhythmogenesis. Cardiovasc Res. 2002;54:462–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Ohtani K, Yutani C, Nagata S, Koretsune Y, Hori M, Kamada T. High prevalence of atrial fibrosis in patients with dilated cardiomyopathy. J Am Coll Cardiol. 1995;25:1162–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Bailey GW, Braniff BA, Hancock EW, Cohn KE. Relation of left atrial pathology to atrial fibrillation in mitral valvular disease. Ann Intern Med. 1968;69:13–20.PubMedCrossRefGoogle Scholar
  21. 21.
    Everett TH, Wilson EE, Verheule S, Guerra JM, Foreman S, Olgin JE. Structural atrial remodeling alters the substrate and spatiotemporal organization of atrial fibrillation: a comparison in canine models of structural and electrical atrial remodeling. Am J Physiol Heart Circ Physiol. 2006;291:H2911–23.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Hanna N, Cardin S, Leung TK, Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res. 2004;63:236–44.PubMedCrossRefGoogle Scholar
  24. 24.
    Lee KW, Everett TH, Rahmutula D, Guerra JM, Wilson E, Ding C, Olgin JE. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation. 2006;114:1703–12.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999;100:87–95.PubMedCrossRefGoogle Scholar
  26. 26.
    Sanders P, Morton JB, Davidson NC, Spence SJ, Vohra JK, Sparks PB, Kalman JM. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. Circulation. 2003;108:1461–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Yucel H, Kaya H, Zorlu A, Yildirimli K, Sancakdar E, Gunes H, Kurt R, Ozgul U, Turgut OO, Yilmaz MB. Cancer antigen 125 levels and increased risk of new-onset atrial fibrillation. Herz. 2015;40(Suppl 2):119–24.PubMedCrossRefGoogle Scholar
  28. 28.
    Kaya H, Zorlu A, Yucel H, Tatlisu MA, Kivrak T, Coskun A, Yilmaz MB. Higher cancer antigen 125 level is associated with the presence of permanent atrial fibrillation in systolic heart failure patients. Acta Cardiol. 2016;71:61–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A, Nattel S. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation. 2000;101:2631–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55:2299–307.PubMedCrossRefGoogle Scholar
  32. 32.
    Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res. 2003;60:315–25.PubMedCrossRefGoogle Scholar
  33. 33.
    van Eickels M, Grohe C, Lobbert K, Stimpel M, Vetter H. Angiotensin converting enzyme inhibitors block mitogenic signalling pathways in rat cardiac fibroblasts. Naunyn Schmiedebergs Arch Pharmacol. 1999;359:394–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Swaminathan PD, Purohit A, Soni S, Voigt N, Singh MV, Glukhov AV, Gao Z, He BJ, Luczak ED, Joiner ML, Kutschke W, Yang J, Donahue JK, Weiss RM, Grumbach IM, Ogawa M, Chen PS, Efimov I, Dobrev D, Mohler PJ, Hund TJ, Anderson ME. Oxidized CaMKII causes cardiac sinus node dysfunction in mice. J Clin Invest. 2011;121:3277–88.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Purohit A, Rokita AG, Guan X, Chen B, Koval OM, Voigt N, Neef S, Sowa T, Gao Z, Luczak ED, Stefansdottir H, Behunin AC, Li N, El-Accaoui RN, Yang B, Swaminathan PD, Weiss RM, Wehrens XH, Song LS, Dobrev D, Maier LS, Anderson ME. Oxidized Ca(2+)/calmodulin-dependent protein kinase II triggers atrial fibrillation. Circulation. 2013;128:1748–57.PubMedCrossRefGoogle Scholar
  36. 36.
    Nascimento BC, Pereira SB, Ribeiro GS, Mesquita ET. Beta1-adrenergic receptor polymorphisms associated with atrial fibrillation in systolic heart failure. Arq Bras Cardiol. 2012;98:384–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013;61:e6–75.PubMedCrossRefGoogle Scholar
  38. 38.
    Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekvål TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793–867.PubMedCrossRefGoogle Scholar
  39. 39.
    Tomassoni G. How to define cardiac resynchronization therapy response. J Innov Card Rhythm Manag. 2016;7:S1–7.CrossRefGoogle Scholar
  40. 40.
    Stellbrink C, Breithardt OA, Sinha AM, Hanrath P. How to discriminate responders from non-responders to cardiac resynchronisation therapy. Eur Heart J. 2004;6(Suppl D):D101–5.Google Scholar
  41. 41.
    Hess PL, Jackson KP, Hasselblad V, Al-Khatib SM. Is cardiac resynchronization therapy an antiarrhythmic therapy for atrial fibrillation? A systematic review and meta-analysis. Curr Cardiol Rep. 2013;15:330.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Gasparini M, Steinberg JS, Arshad A, Regoli F, Galimberti P, Rosier A, Daubert JC, Klersy C, Kamath G, Leclercq C. Resumption of sinus rhythm in patients with heart failure and permanent atrial fibrillation undergoing cardiac resynchronization therapy: a longitudinal observational study. Eur Heart J. 2010;31:976–83.PubMedCrossRefGoogle Scholar
  43. 43.
    Fung JW, Yu CM, Chan JY, Chan HC, Yip GW, Zhang Q, Sanderson JE. Effects of cardiac resynchronization therapy on incidence of atrial fibrillation in patients with poor left ventricular systolic function. Am J Cardiol. 2005;96:728–31.PubMedCrossRefGoogle Scholar
  44. 44.
    D’Ascia SL, D’Ascia C, Marino V, Lombardi A, Santulli R, Chiariello M, Santulli G. Cardiac resynchronisation therapy response predicts occurrence of atrial fibrillation in non-ischaemic dilated cardiomyopathy. Int J Clin Pract. 2011;65:1149–55.PubMedCrossRefGoogle Scholar
  45. 45.
    Brenyo A, Link MS, Barsheshet A, Moss AJ, Zareba W, Wang PJ, McNitt S, Huang D, Foster E, Estes M, Solomon SD, Goldenberg I. Cardiac resynchronization therapy reduces left atrial volume and the risk of atrial tachyarrhythmias in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2011;58:1682–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JG, Freemantle N, Erdmann E. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation. 2006;114:18–25.PubMedCrossRefGoogle Scholar
  47. 47.
    Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.PubMedCrossRefGoogle Scholar
  48. 48.
    Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J. 2015;36:3250–7.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, ESC Committee for Practice Guidelines CPG. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–47.PubMedCrossRefGoogle Scholar
  50. 50.
    January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW, American COCHATFOPG. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;2014(64):e1–76.CrossRefGoogle Scholar
  51. 51.
    Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.PubMedCrossRefGoogle Scholar
  52. 52.
    Mason PK, Lake DE, DiMarco JP, Ferguson JD, Mangrum JM, Bilchick K, Moorman LP, Moorman JR. Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. Am J Med. 2012;125(603):e1–6.Google Scholar
  53. 53.
    Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA. 2015;314:1030–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.PubMedCrossRefGoogle Scholar
  55. 55.
    Ruiz-Gimenez N, Suarez C, Gonzalez R, Nieto JA, Todoli JA, Samperiz AL, Monreal M. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:26–31.PubMedCrossRefGoogle Scholar
  56. 56.
    Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58:395–401.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Senoo K, Proietti M, Lane DA, Lip GY. Evaluation of the HAS-BLED, ATRIA, and ORBIT bleeding risk scores in patients with atrial fibrillation taking warfarin. Am J Med. 2016;129:600–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Roldán V, Marín F, Fernández H, Manzano-Fernandez S, Gallego P, Valdés M, Vicente V, Lip GYH. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013;143:179–84.PubMedCrossRefGoogle Scholar
  59. 59.
    Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail. 2015;17:1192–200.PubMedCrossRefGoogle Scholar
  60. 60.
    Ferreira J, Ezekowitz MD, Connolly SJ, Brueckmann M, Fraessdorf M, Reilly PA, Yusuf S, Wallentin L, RE-LY I. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail. 2013;15:1053–61.PubMedCrossRefGoogle Scholar
  61. 61.
    Andrade JG, Macle L, Nattel S, Verma A, Cairns J. Contemporary atrial fibrillation management: a comparison of the current AHA/ACC/HRS, CCS, and ESC guidelines. Can J Cardiol. 2017;33:965–76.PubMedCrossRefGoogle Scholar
  62. 62.
    Meier B, Blaauw Y, Khattab AA, Lewalter T, Sievert H, Tondo C, Glikson M, Document R. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. Europace. 2014;16:1397–416.PubMedCrossRefGoogle Scholar
  63. 63.
    Brown LAE, Boos CJ. Atrial fibrillation and heart failure: factors influencing the choice of oral anticoagulant. Int J Cardiol. 2017;227:863–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Kareti KR, Chiong JR, Hsu SS, Miller AB. Congestive heart failure and atrial fibrillation: rhythm versus rate control. J Cardiac Fail. 2005;11:164–72.CrossRefGoogle Scholar
  65. 65.
    Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol. 2013;36:122–33.PubMedCrossRefGoogle Scholar
  66. 66.
    Waldo AL. Rate control versus rhythm control in atrial fibrillation: lessons learned from clinical trials of atrial fibrillation. Prog Cardiovasc Dis. 2015;58:168–76.PubMedCrossRefGoogle Scholar
  67. 67.
    Perez A, Touchette DR, DiDomenico RJ, Stamos TD, Walton SM. Comparison of rate control versus rhythm control for management of atrial fibrillation in patients with coexisting heart failure: a cost-effectiveness analysis. Pharmacotherapy. 2011;31:552–65.PubMedCrossRefGoogle Scholar
  68. 68.
    Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O’Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL, Atrial FACHFI. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–77.PubMedCrossRefGoogle Scholar
  69. 69.
    Henrard V, Ducharme A, Khairy P, Gisbert A, Roy D, Levesque S, Talajic M, Thibault B, Racine N, White M, Guerra PG, Tardif JC, AF-CHF I. Cardiac remodeling with rhythm versus rate control strategies for atrial fibrillation in patients with heart failure: insights from the AF-CHF echocardiographic sub-study. Int J Cardiol. 2013;165:430–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Shelton RJ, Clark AL, Goode K, Rigby AS, Houghton T, Kaye GC, Cleland JG. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart. 2009;95:924–30.PubMedCrossRefGoogle Scholar
  71. 71.
    Hagens VE, Crijns HJ, Van Veldhuisen DJ, Den Van, Berg MP, Rienstra M, Ranchor AV, Bosker HA, Kamp O, Tijssen JG, Veeger NJ, Van Gelder IC, RAte CVECFPAFSG. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J. 2005;149:1106–11.PubMedCrossRefGoogle Scholar
  72. 72.
    Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality ON dofetilide (DIAMOND) substudy. Circulation. 2001;104:292–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Al Halabi S, Qintar M, Hussein A, Alraies MC, Jones DG, Wong T, MacDonald MR, Petrie MC, Cantillon D, Tarakji KG, Kanj M, Bhargava M, Varma N, Baranowski B, Wilkoff BL, Wazni O, Callahan T, Saliba W, Chung MK. Catheter ablation for atrial fibrillation in heart failure patients: a meta-analysis of randomized controlled trials. JACC Clin Electrophysiol. 2015;1:200–9.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Ciszewski J, Maciag A, Kowalik I, Syska P, Lewandowski M, Farkowski MM, Borowiec A, Chwyczko T, Pytkowski M, Szwed H, Sterlinski M. Comparison of the rhythm control treatment strategy versus the rate control strategy in patients with permanent or long-standing persistent atrial fibrillation and heart failure treated with cardiac resynchronization therapy—a pilot study of Cardiac Resynchronization in Atrial Fibrillation Trial (Pilot-CRAfT): study protocol for a randomized controlled trial. Trials. 2014;15:386.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Sardu C, Santamaria M, Rizzo MR, Barbieri M, di Marino M, Paolisso G, Santulli G, Marfella R. Telemonitoring in heart failure patients treated by cardiac resynchronisation therapy with defibrillator (CRT-D): the TELECART Study. Int J Clin Pract. 2016;70:569–76.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Cooper HA, Bloomfield DA, Bush DE, Katcher MS, Rawlins M, Sacco JD, Chandler M, AFFIRM I. Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] Study). Am J Cardiol. 2004;93:1247–53.PubMedCrossRefGoogle Scholar
  77. 77.
    Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JGP, Kingma JH, Crijns HJGM, Van Gelder IC. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. J Am Coll Cardiol. 2004;43:241–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP, RACE III. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363–73.PubMedCrossRefGoogle Scholar
  79. 79.
    Zeng WT, Liu ZH, Li ZY, Zhang M, Cheng YJ. Digoxin use and adverse outcomes in patients with atrial fibrillation. Medicine (Baltimore). 2016;95:e2949.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Qureshi W, O’Neal WT, Soliman EZ, Al-Mallah MH. Systematic review and meta-analysis of mortality and digoxin use in atrial fibrillation. Cardiol J. 2016;23:333–43.PubMedCrossRefGoogle Scholar
  81. 81.
    Joglar JA, Acusta AP, Shusterman NH, Ramaswamy K, Kowal RC, Barbera SJ, Hamdan MH, Page RL. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J. 2001;142:498–501.PubMedCrossRefGoogle Scholar
  82. 82.
    Kato N, Naoko K, Kinugawa K, Koichiro K, Teruhiko I, Hironori M, Hisataka M, Toshiro I, Masaru H, Atsushi Y, Nagai R, Ryozo N. Differential impacts of achieved heart rate and achieved dose of β-blocker on clinical outcomes in heart failure with and without atrial fibrillation. Int J Cardiol. 2014;173:331–3.PubMedCrossRefGoogle Scholar
  83. 83.
    Barywani S, Petzold M. Prognostic impact of heart rate in elderly with systolic heart failure and concomitant atrial fibrillation. Scand Cardiovasc J. 2017;51:190–6.PubMedCrossRefGoogle Scholar
  84. 84.
    Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD, Beta-Blockers IHFCG. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384:2235–43.PubMedCrossRefGoogle Scholar
  85. 85.
    Miller RJ, Howlett JG, Chiu MH, Southern DA, Knudtson M, Wilton SB. Relationships among achieved heart rate, β-blocker dose and long-term outcomes in patients with heart failure with atrial fibrillation. Open Heart. 2016;3:e000520.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Bohm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson A, Wikstrand J, Kotecha D. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39:26–35.PubMedCrossRefGoogle Scholar
  87. 87.
    Rienstra M, Damman K, Mulder BA, Van Gelder IC, McMurray JJ, Van Veldhuisen DJ. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail. 2013;1:21–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Gupta T, Khera S, Kolte D, Aronow WS, Iwai S. Antiarrhythmic properties of ranolazine: a review of the current evidence. Int J Cardiol. 2015;187:66–74.PubMedCrossRefGoogle Scholar
  89. 89.
    Verrier RL, Kumar K, Nieminen T, Belardinelli L. Mechanisms of ranolazine’s dual protection against atrial and ventricular fibrillation. Europace. 2013;15:317–24.PubMedCrossRefGoogle Scholar
  90. 90.
    Black-Maier EW, Pokorney SD, Barnett AS, Liu P, Shrader P, Ng J, Goldberger JJ, Zareba W, Daubert JP, Grant AO, Piccini JP. Ranolazine reduces atrial fibrillatory wave frequency. Europace. 2017;19:1096–100.PubMedGoogle Scholar
  91. 91.
    Burashnikov A, Di Diego JM, Barajas-Martínez H, Hu D, Zygmunt AC, Cordeiro JM, Moise NS, Kornreich BG, Belardinelli L, Antzelevitch C. Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure. Circ Heart Fail. 2014;7:627–33.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Reiffel JA, Camm AJ, Belardinelli L, Zeng D, Karwatowska-Prokopczuk E, Olmsted A, Zareba W, Rosero S, Kowey P, HARMONY I. The HARMONY trial: combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism. Circ Arrhythm Electrophysiol. 2015;8:1048–1056.Google Scholar
  93. 93.
    De Ferrari GM, Maier LS, Mont L, Schwartz PJ, Simonis G, Leschke M, Gronda E, Boriani G, Darius H, Guillamón Torán L, Savelieva I, Dusi V, Marchionni N, Quintana Rendón M, Schumacher K, Tonini G, Melani L, Giannelli S, Alberto Maggi C, Camm AJ, RAFFAELLO IOSAFLOPCAI. Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study. Heart Rhythm. 2015;12:872–8.PubMedCrossRefGoogle Scholar
  94. 94.
    Seoane L, Baranchuk A, Conde D. Vernakalant for the conversion of atrial fibrillation of recent onset. Medicina (B Aires). 2015;75:239–44.PubMedGoogle Scholar
  95. 95.
    Buccelletti F, Iacomini P, Botta G, Marsiliani D, Carroccia A, Gentiloni Silveri N, Franceschi F. Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines agency approval: systematic review and meta-analysis. J Clin Pharmacol. 2012;52:1872–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Cosin-Sales J, Loscos A, Peiró A, Sorando MR, Buendía F, Ruescas L. Real-world data on the efficacy of vernakalant for pharmacological cardioversion in patients with recent-onset atrial fibrillation. Rev Esp Cardiol (Engl Ed). 2016;69:619–20.PubMedCrossRefGoogle Scholar
  97. 97.
    Savelieva I, Graydon R, Camm AJ. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines. Europace. 2014;16:162–73.PubMedCrossRefGoogle Scholar
  98. 98.
    Tadros R, Nattel S, Andrade JG. Dronedarone: basic pharmacology and clinical use. Card Electrophysiol Clin. 2016;8:453–65.PubMedCrossRefGoogle Scholar
  99. 99.
    Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crijns H, Amlie J, Carlsen J, Dronedarone SG. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678–87.PubMedCrossRefGoogle Scholar
  100. 100.
    Borer JS, Deedwania PC, Kim JB, Böhm M. Benefits of heart rate slowing with ivabradine in patients with systolic heart failure and coronary artery disease. Am J Cardiol. 2016;118:1948–53.PubMedCrossRefGoogle Scholar
  101. 101.
    Frommeyer G, Sterneberg M, Dechering DG, Ellermann C, Bögeholz N, Kochhäuser S, Pott C, Fehr M, Eckardt L. Effective suppression of atrial fibrillation by ivabradine: novel target for an established drug. Int J Cardiol. 2017;236:237–43.PubMedCrossRefGoogle Scholar
  102. 102.
    Turley SL, Francis KE, Lowe DK, Cahoon WD. Emerging role of ivabradine for rate control in atrial fibrillation. Ther Adv Cardiovasc Dis. 2016;10:348–52.PubMedCrossRefGoogle Scholar
  103. 103.
    Sunman H, Aytemir K, Yorgun H, Canpolat U, Yalçin MU, Maharjan N, Asil S, Şahiner L, Kaya B, Özer N, Oto A. Evaluating the efficacy and safety of internal cardioversion with implantable cardioverter defibrillator device for atrial fibrillation in systolic heart failure patients. Ann Noninvasive Electrocardiol. 2016;21:181–8.PubMedCrossRefGoogle Scholar
  104. 104.
    Lellouche N, De Diego C, Vaseghi M, Buch E, Cesario DA, Mahajan A, Wiener I, Fonarow GC, Boyle NG, Shivkumar K. Cardiac resynchronization therapy response is associated with shorter duration of atrial fibrillation. Pacing Clin Electrophysiol. 2007;30:1363–8.PubMedCrossRefGoogle Scholar
  105. 105.
    Hugl B, Bruns HJ, Unterberg-Buchwald C, Grosse A, Stegemann B, Lauer B, Geller JC, Gasparini M. Atrial fibrillation burden during the post-implant period after crt using device-based diagnostics. J Cardiovasc Electrophysiol. 2006;17:813–7.PubMedCrossRefGoogle Scholar
  106. 106.
    Shi LZ, Heng R, Liu SM, Leng FY. Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: a meta-analysis of randomized controlled trials. Exp Ther Med. 2015;10:816–22.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Wang M, Cai S, Ding W, Deng Y, Zhao Q. Efficacy and effects on cardiac function of radiofrequency catheter ablation vs. direct current cardioversion of persistent atrial fibrillation with left ventricular systolic dysfunction. PLoS One. 2017;12:e0174510.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Ganesan AN, Nandal S, Lüker J, Pathak RK, Mahajan R, Twomey D, Lau DH, Sanders P. Catheter ablation of atrial fibrillation in patients with concomitant left ventricular impairment: a systematic review of efficacy and effect on ejection fraction. Heart Lung Circ. 2015;24:270–80.PubMedCrossRefGoogle Scholar
  109. 109.
    Khan MN, Jaïs P, Cummings J, Di Biase L, Sanders P, Martin DO, Kautzner J, Hao S, Themistoclakis S, Fanelli R, Potenza D, Massaro R, Wazni O, Schweikert R, Saliba W, Wang P, Al-Ahmad A, Beheiry S, Santarelli P, Starling RC, Dello Russo A, Pelargonio G, Brachmann J, Schibgilla V, Bonso A, Casella M, Raviele A, Haïssaguerre M, Natale A, PABA-CHF I. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008;359:1778–85.PubMedCrossRefGoogle Scholar
  110. 110.
    Lobo TJ, Pachon CT, Pachon JC, Pachon EI, Pachon MZ, Pachon JC, Santillana TG, Zerpa JC, Albornoz RN, Jatene AD. Atrial fibrillation ablation in systolic dysfunction: clinical and echocardiographic outcomes. Arq Bras Cardiol. 2015;104:45–52.PubMedPubMedCentralGoogle Scholar
  111. 111.
    Anselmino M, Matta M, D’Ascenzo F, Bunch TJ, Schilling RJ, Hunter RJ, Pappone C, Neumann T, Noelker G, Fiala M, Bertaglia E, Frontera A, Duncan E, Nalliah C, Jais P, Weerasooriya R, Kalman JM, Gaita F. Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2014;7:1011–8.PubMedCrossRefGoogle Scholar
  112. 112.
    Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, McDonagh TA, Underwood SR, Markides V, Wong T. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol. 2013;61:1894–903.PubMedCrossRefGoogle Scholar
  113. 113.
    Prabhu S, Taylor AJ, Costello BT, Kaye DM, McLellan AA, Voskoboinik A, Sugumar H, Lockwood SM, Stokes MB, Pathik B, Nalliah CJ, Wong GR, Azzopardi SM, Gutman S, Lee G, Layland J, Mariani JA, Ling LH, Kalman JM, Kistler PM. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction (CAMERA-MRI). J Am Coll Cardiol. 2017;70:1949–61.Google Scholar
  114. 114.
    Marrouche NF, Brachmann J, CASTLE-AF SC. Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF)—study design. Pacing Clin Electrophysiol. 2009;32:987–94.PubMedCrossRefGoogle Scholar
  115. 115.
    Hirayama Y, Atarashi H, Kobayashi Y, Horie T, Iwasaki Y, Maruyama M, Miyauchi Y, Ohara T, Yashima M, Takano T. Angiotensin-converting enzyme inhibitor therapy inhibits the progression from paroxysmal atrial fibrillation to chronic atrial fibrillation. Circ J. 2005;69:671–6.PubMedCrossRefGoogle Scholar
  116. 116.
    Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 2003;107:2926–31.PubMedCrossRefGoogle Scholar
  117. 117.
    Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cere E, Tognoni G, Cohn JN. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149:548–57.PubMedCrossRefGoogle Scholar
  118. 118.
    Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 2003;41:2197–204.PubMedCrossRefGoogle Scholar
  119. 119.
    Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, Vincent J, Pitt B, EMPHASIS-HF SI. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012;59:1598–603.PubMedCrossRefGoogle Scholar
  120. 120.
    Simopoulos V, Tagarakis G, Hatziefthimiou A, Skoularigis I, Triposkiadis F, Trantou V, Tsilimingas N, Aidonidis I. Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study. Clin Res Cardiol. 2015;104:31–7.PubMedCrossRefGoogle Scholar
  121. 121.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task FM, Document R. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.PubMedCrossRefGoogle Scholar
  122. 122.
    Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, Ellinor PT, Cheng S, Vasan RS, Lee DS, Wang TJ, Levy D, Benjamin EJ, Ho JE. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation. 2016;133:484–92.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, Oh JK, Leibson C, Montgomery SC, Seward JB. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40:1636–44.PubMedCrossRefGoogle Scholar
  124. 124.
    Sobue Y, Watanabe E, Lip GYH, Koshikawa M, Ichikawa T, Kawai M, Harada M, Inamasu J, Ozaki Y. Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF). Heart Vessels. 2017.  https://doi.org/10.1007/s00380-017-1073-5.
  125. 125.
    Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol. 2016;203:660–6.PubMedCrossRefGoogle Scholar
  126. 126.
    Nanayakkara S, Kaye DM. Targets for heart failure with preserved ejection fraction. Clin Pharmacol Ther. 2017;102:228–37.PubMedCrossRefGoogle Scholar
  127. 127.
    Shang X, Lu R, Liu M, Xiao S, Dong N. Heart rate and outcomes in patients with heart failure with preserved ejection fraction: a dose-response meta-analysis. Medicine (Baltimore). 2017;96:e8431.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Black-Maier E, Ren X, Steinberg BA, Green CL, Barnett AS, Rosa NS, Al-Khatib SM, Atwater BD, Daubert JP, Frazier-Mills C, Grant AO, Hegland DD, Jackson KP, Jackson LR, Koontz JI, Lewis RK, Sun AY, Thomas KL, Bahnson TD, Piccini JP. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. Heart Rhythm. 2017.  https://doi.org/10.1016/j.hrthm.2017.12.001.
  129. 129.
    Mohmand-Borkowski A, Tang WH. Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases. Heart Fail Rev. 2014;19:295–304.PubMedCrossRefGoogle Scholar
  130. 130.
    Kubo T, Kitaoka H, Okawa M, Hirota T, Hayato K, Yamasaki N, Matsumura Y, Yabe T, Takata J, Doi YL. Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy. Results from Kochi RYOMA Study. Circ J. 2009;73:1599–605.PubMedCrossRefGoogle Scholar
  131. 131.
    Magnusson P, Mörner S, Gadler F, Karlsson J. Health-related quality of life in hypertrophic cardiomyopathy patients with implantable defibrillators. Health Qual Life Outcomes. 2016;14:62.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM, Maron MS, Maron BJ. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation. 2017;136:2420–36.PubMedGoogle Scholar
  133. 133.
    Rowin EJ, Maron MS, Chan RH, Hausvater A, Wang W, Rastegar H, Maron BJ. Interaction of adverse disease related pathways in hypertrophic cardiomyopathy. Am J Cardiol. 2017;120:2256–64.PubMedCrossRefGoogle Scholar
  134. 134.
    Duytschaever M, Vijgen J, Tavernier R. Atrial fibrillation in hypertrophic cardiomyopathy: another indication for circumferential pulmonary vein ablation. Acta Cardiol. 2006;61:193–6.PubMedCrossRefGoogle Scholar
  135. 135.
    Maagh P, Plehn G, Christoph A, Oernek A, Meissner A. Impact of cryoballoon ablation in hypertrophic cardiomyopathy-related heart failure due to paroxysmal atrial fibrillation. A comparative case series. Int J Med Sci. 2016;13:664–72.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Brownlie SE, Cobb MA. Observations on the development of congestive heart failure in Irish wolfhounds with dilated cardiomyopathy. J Small Anim Pract. 1999;40:371–7.PubMedCrossRefGoogle Scholar
  137. 137.
    Morales M, Ynaraja E, Montoya JA. Dilated cardiomyopathy in Presa canario dogs: ECG findings. J Vet Med A Physiol Pathol Clin Med. 2001;48:577–80.PubMedCrossRefGoogle Scholar
  138. 138.
    Takemoto M, Sakamoto M, Kawagoe J, Goto K, Baba H, Noma M, Origuchi H, Yoshimura H, Sese A, Yamamoto H. Effect of biventricular pacing therapy in patients with dilated cardiomyopathy with severe congestive heart failure. Jpn J Thorac Cardiovasc Surg. 2004;52:175–80.PubMedCrossRefGoogle Scholar
  139. 139.
    Agarwal AK, Venugopalan P. Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2001;3:437–40.PubMedCrossRefGoogle Scholar
  140. 140.
    Ling LH, Taylor AJ, Ellims AH, Iles LM, McLellan AJ, Lee G, Kumar S, Lee G, Teh A, Medi C, Kaye DM, Kalman JM, Kistler PM. Sinus rhythm restores ventricular function in patients with cardiomyopathy and no late gadolinium enhancement on cardiac magnetic resonance imaging who undergo catheter ablation for atrial fibrillation. Heart Rhythm. 2013;10:1334–9.PubMedCrossRefGoogle Scholar
  141. 141.
    Sohinki D, Ho J, Srinivasan N, Collins LJ, Obel OA. Outcomes after atrioventricular node ablation and biventricular pacing in patients with refractory atrial fibrillation and heart failure: a comparison between non-ischaemic and ischaemic cardiomyopathy. Europace. 2014;16:880–6.PubMedCrossRefGoogle Scholar
  142. 142.
    Levy F, Rusinaru D, Maréchaux S, Charles V, Peltier M, Tribouilloy C. Determinants and prognosis of atrial fibrillation in patients with aortic stenosis. Am J Cardiol. 2015;116:1541–6.PubMedCrossRefGoogle Scholar
  143. 143.
    Chopard R, Teiger E, Meneveau N, Chocron S, Gilard M, Laskar M, Eltchaninoff H, Iung B, Leprince P, Chevreul K, Prat A, Lievre M, Leguerrier A, Donzeau-Gouge P, Fajadet J, Mouillet G, Schiele F, FRANCE-2 I. Baseline characteristics and prognostic implications of pre-existing and new-onset atrial fibrillation after transcatheter aortic valve implantation: results from the FRANCE-2 registry. JACC Cardiovasc Interv. 2015;8:1346–1355.Google Scholar
  144. 144.
    Moretti M, Fabris E, Morosin M, Merlo M, Barbati G, Pinamonti B, Gatti G, Pappalardo A, Sinagra G. Prognostic significance of atrial fibrillation and severity of symptoms of heart failure in patients with low gradient aortic stenosis and preserved left ventricular ejection fraction. Am J Cardiol. 2014;114:1722–8.PubMedCrossRefGoogle Scholar
  145. 145.
    Hioki H, Watanabe Y, Kozuma K, Nara Y, Kawashima H, Nagura F, Nakashima M, Kataoka A, Yamamoto M, Naganuma T, Araki M, Tada N, Shirai S, Yamanaka F, Hayashida K, OCEAN-TAVI I. Timing of susceptibility to mortality and heart failure in patients with preexisting atrial fibrillation after transcatheter aortic valve implantation. Am J Cardiol. 2017;120:1618–25.PubMedCrossRefGoogle Scholar
  146. 146.
    Jung SW, Sun W, Griffiths LG, Kittleson MD. Atrial fibrillation as a prognostic indicator in medium to large-sized dogs with myxomatous mitral valvular degeneration and congestive heart failure. J Vet Intern Med. 2016;30:51–7.PubMedCrossRefGoogle Scholar
  147. 147.
    Suri RM, Vanoverschelde JL, Grigioni F, Schaff HV, Tribouilloy C, Avierinos JF, Barbieri A, Pasquet A, Huebner M, Rusinaru D, Russo A, Michelena HI, Enriquez-Sarano M. Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets. JAMA. 2013;310:609–16.PubMedCrossRefGoogle Scholar
  148. 148.
    Takahashi Y, Abe Y, Sasaki Y, Bito Y, Morisaki A, Nishimura S, Shibata T. Mitral valve repair for atrial functional mitral regurgitation in patients with chronic atrial fibrillation. Interact Cardiovasc Thorac Surg. 2015;21:163–8.PubMedCrossRefGoogle Scholar
  149. 149.
    Acharya D, Sanam K, Revilla-Martinez M, Hashim T, Morgan CJ, Pamboukian SV, Loyaga-Rendon RY, Tallaj JA. Infections, arrhythmias, and hospitalizations on home intravenous inotropic therapy. Am J Cardiol. 2016;117:952–6.PubMedCrossRefGoogle Scholar
  150. 150.
    Deshmukh A, Kim G, Burke M, Anyanwu E, Jeevanandam V, Uriel N, Tung R, Ozcan C. Atrial arrhythmias and electroanatomical remodeling in patients with left ventricular assist devices. J Am Heart Assoc. 2017.  https://doi.org/10.1161/JAHA.116.005340.
  151. 151.
    Enriquez AD, Calenda B, Gandhi PU, Nair AP, Anyanwu AC, Pinney SP. Clinical impact of atrial fibrillation in patients with the HeartMate II left ventricular assist device. J Am Coll Cardiol. 2014;64:1883–90.PubMedCrossRefGoogle Scholar
  152. 152.
    Mahoney P, Kimmel S, DeNofrio D, Wahl P, Loh E. Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. Am J Cardiol. 1999;83:1544–7.PubMedCrossRefGoogle Scholar
  153. 153.
    Oezpeker C, Zittermann A, Pühler T, Ensminger S, Gummert JF, Morshuis M. Permanent atrial fibrillation and 2 year clinical outcomes in patients with a left ventricular assist device implant. ASAIO J. 2017;63:419–24.PubMedCrossRefGoogle Scholar
  154. 154.
    Stulak JM, Deo S, Schirger J, Aaronson KD, Park SJ, Joyce LD, Daly RC, Pagani FD. Preoperative atrial fibrillation increases risk of thromboembolic events after left ventricular assist device implantation. Ann Thorac Surg. 2013;96:2161–7.PubMedCrossRefGoogle Scholar
  155. 155.
    Xia Y, Stern D, Friedmann P, Goldstein D. Preoperative atrial fibrillation may not increase thromboembolic events in left ventricular assist device recipients on midterm follow-up. J Heart Lung Transplant. 2016;35:906–12.PubMedCrossRefGoogle Scholar
  156. 156.
    Xuereb L, Go PH, Kaur B, Akrawe S, Nemeh HW, Borgi J, Williams CT, Paone G, Morgan JA. Impact of preoperative atrial fibrillation on postoperative thromboembolic events after left ventricular assist device implantation. Ann Thorac Surg. 2016;102:1543–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of MedicineHealth + Hospitals/MetropolitanNew YorkUSA
  2. 2.New York Medical CollegeValhallaUSA
  3. 3.Division of Cardiology, Department of MedicineHealth + Hospitals/MetropolitanNew YorkUSA

Personalised recommendations